

Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), ("Rain") today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results.

Conference Call and Webcast Details:

Date: August 10, 2023

Time: 2:00 pm PT (5:00 pm ET)

Dial In Numbers: 1 (888) 886-7786 (U.S. Toll Free) / 1 (416) 764-8658 (International)

Conference ID: 29873479

Webcast Link: https://viaavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f

A replay of the call will be available by visiting the "[Events](#)" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Oncology Inc.

Rain Oncology Inc. is a precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.

Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53.

Media Contact

Mahima Agochiya

Rain Oncology

magochiya@rainoncology.com

Investor Contact

Dan Ferry

LifeSci Advisors

+1.617.430.7576

daniel@lifesciadvisors.com